Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768316 | 1.00 | PRCP (1.00) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL31158625 | 1.00 | PRCP (1.00) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL1012767 | 1.00 | PRCP (1.00) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL31569038 | 0.87 | PRCP (0.77) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL9533138 | 0.84 | PRCP (0.73) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL28209057 | 0.83 | PRCP (0.71) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL4144168 | 0.83 | PRCP (0.71) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL16968353 | 0.83 | PRCP (0.71) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL24845654 | 0.83 | PRCP (0.71) | PRCPGAASLC22A1GID4RECQL | |
| SCHEMBL9530395 | 0.81 | PRCP (0.67) | PRCPGAASLC22A1GID4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | PRCP 211/4885GAA 115/4885SLC22A1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.